Natera Q1 revenue $696.6M (+39% YoY); raises FY2026 guidance by $120M to $2.78B midpt

Natera, Inc.

2026-Q1 EPS reported -$0.60 revenue$696,644,000

Revenue $696.6M (+38.8% YoY); tests processed 1,013,600 (+18.5%), oncology tests up 54.4%.
Net loss $85.1M ($0.60/sh) vs $66.9M ($0.50) prior year; positive cash inflow $11.8M.
Raises FY2026 revenue guidance by $120M midpoint to $2.74B-$2.82B; gross margin expected 64%-66%.
Operating expenses $538.6M (+36.0%) on headcount growth and clinical trial expenses.
Cash and equivalents $1,087.9M; debt $80.3M under line of credit.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Natera, Inc. reported first quarter ended March 31, 2026 results: revenue $696.6 million, net income $85.1 million, EPS ($0.60) per diluted share. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $696.6 million
Net income: $85.1 million
EPS: ($0.60) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights • Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. • Generated a gross margin 1 of 64.7% in the first quarter of 2026,

View on SEC.gov

Browse all earnings releases →

Natera, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-032101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.